George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 Apr 11. doi: 10.1007/s41669-024-00483-w
Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7
Marsal JR, Urreta-Barallobre I, Ubeda-Carrillo M, Osorio D, Lumbreras B, Lora D, Fernandez-Felix BM, Oristrell G, Rodenas-Alesina E, Herrador L, Ballesteros M, Zamora J, Pijoan JI, Ribera A, Ferreira-Gonzalez I. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights. Trials. 2022 Dec 21;23(1):1037. doi: 10.1186/s13063-022-06977-4
Zhang Y, Mayorga ME, Ivy J, Hassmiller Lich K, Swann JL. Modeling the impact of nonpharmaceutical interventions on COVID-19 transmission in K-12 schools. MDM Policy Pract. 2022 Dec 3;7(2):238146832. doi: 10.1177/23814683221140866
Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3
Sutphin J, DiSantostefano RL, Leach C, Hauber B, Mansfield C. Exploring decisional conflict with measures of numeracy and optimism in a stated preference survey. MDM Policy Pract. 2021 Nov 13;6(2):238146832. doi: 10.1177/23814683211058663
Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Nag A, Martin SA, Mladsi D, Olayinka-Amao O, Purser M, Vekaria RM. The humanistic and economic burden of chronic idiopathic constipation in the USA: a systematic literature review. Clin Exp Gastroenterol. 2020 Jul 16;(13):255-65. doi: 10.2147/CEG.S239205
Dattilo J, Siperstein GN, McDowell ED, Schleien SJ, Whitaker E, Block M, Spolidoro M, Bari J, Hall A. Perceptions of programming needs for inclusive leisure services. JPRA. 2019 Oct 24;37(4):70-91. doi: 10.18666/JPRA-2019-9514
Boeri M, Myers K, Ervin C, Marren A, DiBonaventura M, Cappelleri JC, Hauber B, Rubin DT. Patient and physician preferences for ulcerative colitis treatments in the United States. Clin Exp Gastroenterol. 2019 Jun 11;12:263-78. doi: 10.2147/CEG.S206970
Fehnel S, Fiedorek FT, Nelson L, DiBenedetti D, Spence S, Carson RT. Development and psychometric evaluation of the Diabetic Gastroparesis Symptom Severity Diary. Clin Exp Gastroenterol. 2019 Feb 22;12:93-103. doi: 10.2147/CEG.S184016
Nelson LM, Williams VS, Fehnel SE, Carson RT, MacDougall J, Baird MJ, Tourkodimitris S, Kurtz CB, Johnston JM. Psychometric validation of patient-reported outcome measures assessing chronic constipation. Clin Exp Gastroenterol. 2014 Sep 26;7:385-94.
Ervin CM, Fehnel SE, Baird MJ, Carson RT, Johnston JM, Shiff SJ, Kurtz CB, Mangel AW. Assessment of treatment response in chronic constipation clinical trials. Clin Exp Gastroenterol. 2014 Jun 3;7:191-8. doi: 10.2147/CEG.S58321. eCollection 2014
Bartha E, Davidson T, Brodtkorb T, Carlsson P, Kalman S. Value of information: interim analysis of a randomized, controlled trial of goal-directed hemodynamic treatment for aged patients. Trials. 2013 Jul 9;14:205.